Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbetapentane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 3/20 | 0.95 |
| ▸ | PRCP | P42785 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | THRB | P10828 | 1/20 | 0.95 |
| ▸ | HTT | P42858 | 1/20 | 0.95 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.95 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbetapentane SCHEMBL15516338 | 0.98 | CHRM2 (1.00) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Carbetapentane SCHEMBL67879 | 0.98 | CHRM2 (1.00) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Carbetapentane SCHEMBL5174918 | 0.96 | CHRM2 (0.98) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Caramiphen SCHEMBL181285 | 0.90 | PRCP (1.00) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Carbetapentane SCHEMBL7614465 | 0.89 | CHRM2 (0.84) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Caramiphen SCHEMBL1374820 | 0.89 | ALDH1A1 (1.00) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Caramiphen SCHEMBL10898559 | 0.89 | PRCP (0.97) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL7383119 | 0.88 | ALDH1A1 (0.97) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| SCHEMBL8107029 | 0.88 | PRCP (0.95) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| Carbetapentane SCHEMBL160096 | 0.88 | ALDH1A1 (1.00) | CHRM2CHRM1ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| US-20200222409-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2020-07-16 | — | — | US | disclosed |
| US-10617689-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2020-04-14 | — | — | US | disclosed |
| US-10596160-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2020-03-24 | — | — | US | disclosed |
| EP-2914252-B1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2019-09-04 | — | — | EP | disclosed |
| EP-3482753-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | Pharnext (FR) | 2019-05-15 | — | — | EP | disclosed |
| US-20190008841-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2019-01-10 | — | — | US | disclosed |
| EP-3388062-A1 | COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | Pharnext (FR) | 2018-10-17 | — | — | EP | disclosed |
| US-10092554-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2018-10-09 | — | — | US | disclosed |
| US-20180263989-A1 | THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | PHARNEXT (FR) | 2018-09-20 | — | — | US | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| US-20170049777-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2017-02-23 | — | — | US | disclosed |
| US-20160235693-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2016-08-18 | — | — | US | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| US-20150246044-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | PHARNEXT (FR) | 2015-09-03 | — | — | US | disclosed |
| US-20150231123-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-08-20 | — | — | US | disclosed |
| EP-2892518-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| EP-2727587-A1 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | Pharnext (FR) | 2014-05-07 | — | — | EP | disclosed |
| WO-2014037416-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-2705842-A1 | Therapeutic approaches for treating parkinson's disease | Pharnext (FR) | 2014-03-12 | — | — | EP | disclosed |